HSP90AA1 and cancer: Previous studies have also demonstrated that deletion or inhibition of specific HDACs enhances the sensitivity of cancer cells to Hsp90 inhibitors by increasing the acetylation of key lysine residues, thereby promoting more stable drug interactions (22, 23).